Analyst Reco. CorMedix Inc.

Equities

CRMD

US21900C3088

Market Closed - Nasdaq Other stock markets 01:30:00 27/04/2024 am IST			5-day change	1st Jan Change
5.31 ^USD	+2.31%		+0.57%	+41.22%

15/04	CorMedix's DefenCath Now Commercially Available For US Inpatient Use	MT
15/04	CorMedix Inc. Announces U.S. Inpatient Commercial Availability of DefenCath®? (Taurolidine and Heparin)	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RBC Trims Price Target on CorMedix to $9 From $10, Keeps Outperform Rating, Speculative Risk Qualifier	13/03	MT
RBC Boosts Price Target on CorMedix to $10 From $6 on 'Heightening Prospects of DefenCath Reaching Market,' Keeps Outperform, Speculative Risk	15/11	MT
RBC Initiates CorMedix at Outperform, Speculative Risk With $6 Price Target, Sees DefenCath 'More Likely Than Not to Be Approved'	10/23/10	MT
JMP Securities Adjusts Price Target on CorMedix to $19 From $16, Keeps Market Outperform Rating	19/23/19	MT
JMP Securities Adjusts CorMedix's Price Target to $16 From $14, Keeps Market Perform Rating	01/23/01	MT
Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating	12/22/12	MT
JMP Securities Adjusts CorMedix Price Target to $14 From $19, Maintains Market Outperform Rating	09/22/09	MT
Needham Adjusts CorMedix's Price Target to $12 from $20, Keeps Buy Rating	09/22/09	MT
CORMEDIX : Needham & Co Adjusts CorMedix PT to $29 From $31, Maintains Buy Rating	14/21/14	MT
CORMEDIX : B. Riley Lowers CorMedix' Price Target to $13.50 from $25 After FDA Rejects DefenCath Due to Manufacturing Issues, Keeps Buy Rating	02/21/02	MT
CORMEDIX : Needham Starts CorMedix at Buy With $31 Price Target	17/21/17	MT
CORMEDIX : B. Riley Adjusts CorMedix' Price Target to $25 From $11, Keeps Buy Rating	09/21/09	MT
CORMEDIX : Truist Securities Adjusts CorMedix PT to $35 From $20, Maintains Buy Rating	02/21/02	MT
CORMEDIX : Truist Securities Adjusts CorMedix' Price Target to $35 from $20, Keeps Buy Rating	02/21/02	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer